EGFR and lung cancer: Somatic EGFR kinase domain mutations (EGFRMT) are detected in 10%–20% and 30%–60% of White and Asian non–small cell lung cancer (NSCLC) patients, respectively (2–5), leading to constitutive EGFR kinase activation (6).